Net profit fell 87.63% year-over-year due to lower caffeine prices and higher R&D spending, while biopharmaceutical revenue surged 153% with new product launches. The company advanced its strategic transformation, maintained strong gross margins in biopharma, and increased R&D investment to 42.52% of revenue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.